EMV 3.47% $2.09 emvision medical devices ltd

EMvision Research Notes, page-2699

  1. 4,261 Posts.
    lightbulb Created with Sketch. 1186
    You're looking at an opportunity to buy in at a price below what the largest shareholder paid. You are probably familiar with the $26.5 billion company Keysight right?.

    Meanwhile, most of the ASX seems to be overlooking more solid, less hyped stocks like EMV, focusing instead on flashy, trendy picks of the week.
    However, EMV has been quietly laying the foundation for future growth. The groundwork has been steadily built through strategic partnerships, R&D grants, minimal burn, a fantastic capital structure, cornerstone investors (Keysight) and a clear focus on long-term value creation. This isn’t a company chasing short-term trends; it’s building something truly substantial.

    With commercialisation just around the corner, EMV is poised to shift gears and enter a new growth phase. This is when the hard work pays off and the "rubber meets the road."

    It’s only a matter of time before the market recognises the immense value and potential of this company. Those who get in early, while others are distracted by flashy volume trends, could see a major pay-off when the true potential is realised.

    upload_2024-9-26_15-33-9.png
 
watchlist Created with Sketch. Add EMV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.